Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This protocol was opened to collect long term survival information on subjects enrolled in a previous study which evaluated the impact of neoadjuvant chemotherapy and concomitant chemoradiotherapy with organ preserving optional surgery on overall survival, time to progression, pattern of disease recurrence in patient with locally advanced head and neck cancer. The last surviving subject was last treated in 1989, and was lost to follow up in 2010.
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer |
- Overall survival [ Time Frame: Until Death ] [ Designated as safety issue: No ]To collect long term survival information on subjects treated on a previous protocol which evaluated the the impact of neoadjuvant chemotherapy and concomitant chemoradiotherapy with organ preserving optional surgery on overall survival, time to progression, and pattern of disease recurrence in patients with locally advanced head and neck cancer.
| Enrollment: | 35 |
| Study Start Date: | March 2003 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Treated subjects
Subjects treated on a previous study of locally advanced head and neck cancer
|
Eligibility| Ages Eligible for Study: | 59 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects enrolled on a previous head and neck cancer treatment protocol
Eligibility Criteria:
Eligibility Criteria:
Subjects previously enrolled in a treatment protocol for locally advanced head and neck cancer who met the following criteria:
Patients with Stage IV carcinoma of the nasal or oral cavity, nasopharynx pharynx, larynx, paranasal sinuses, cervical esophagus, or hypopharynx are eligible. Patients with Stage III carcinoma of the nasopharynx, base of tongue and hypopharynx are also eligible. Therapy is given with curative intent.
Prior to entry in the study the resectability and standard treatment options for each patient will be determined during a joint evaluation by a team composed of an attending surgeon, a radiation oncologist and a medical oncologist. In addition the timing and feasibility of surgery will be determined in each patient prior to initiation of therapy. The unequivocal demonstration of distant metastasis confers in eligibility.
- Measurable disease is not required, but all disease will be carefully evaluated.
- Patients must have a histologically or cytologically confirmed diagnosis of squamous cell carcinoma, mucoepidermoid carcinoma or lymphoepithelioma.
- Patients must have not received prior chemotherapy or radiotherapy.
- Patients must have performance status of >60%
- Patients must have a WBC count of >3.5, an ANC count >1500 and a platlet count of >100,000.
- The serum creatinine must be equal to or less than 1.5 m/dlor the calculated creatinine clearance must exceed 50cc/min.
- Patient must be free of significant infection or other severe complicating medical illness.
- Pregnancy will constitute an absolute contraindication to entrance on this protocol.
Contacts and Locations| United States, Illinois | |
| The University of Chicago | |
| Chicago, Illinois, United States, 60653 | |
| Principal Investigator: | Everett E Vokes, MD | University of Chicago |
More Information
No publications provided
| Responsible Party: | University of Chicago |
| ClinicalTrials.gov Identifier: | NCT01187472 History of Changes |
| Other Study ID Numbers: | 12145B |
| Study First Received: | August 20, 2010 |
| Last Updated: | January 15, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Chicago:
|
Head neck cancer advanced |
oral cavity lip larynx |
Additional relevant MeSH terms:
|
Head and Neck Neoplasms Neoplasms by Site Neoplasms |
ClinicalTrials.gov processed this record on May 16, 2013